Mechanism(s) of systolic blood pressure reduction and drug therapy in hypertension

Hypertension

Volumn 50, Issue 1, 2007, Pages 167-171

  Safar, Michel E ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL;

ATHEROSCLEROSIS; AUTOREGULATION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE EJECTION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OXIDATIVE STRESS; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULSE WAVE; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; VASCULAR RESISTANCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; CARDIOMEGALY; CEREBROVASCULAR ACCIDENT; DISEASE PROGRESSION; HEART; HUMANS; HYPERTENSION; KIDNEY; REMISSION INDUCTION; SYSTOLE;

EID: 34250812068     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.088799     Document Type: Conference Paper

References (35)

1. Safar ME, Levy BI, Sruijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107:2864-2869.
2. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrieres J, Bingham A, Yarnell J, Haas B, Montaye M, Ruidavets JB, Ducimetiere P. Residual coronary risk in men aged 50-59 years treated for hypertension and hyperlipidaemia in the population: the PRIME study. J Hypertens. 2004;22:415-423.
3. Black HR. The paradigm has shifted to systolic blood pressure. Hypertension. 1999;34:386-387.
4. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness: definitions and reference values. Am J Hypertens. 2002;15:426-444.
5. Mitchell GF, Vita JA, Larson MG, Parise H, Keyes MJ, Warner E, Vasan RS, Levy D, Benjamin EJ. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation. 2005;112:3722-3728.
6. Levy BI. New aspects in the mechanisms of hypertension and the pathophysiology of the arterial tree. In: Safar ME, ed. Macro- and Microcirculation in Hypertension. London, United Kingdom: Lippincott Williams & Wilkins; 2005:3-12.
7. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-992.
8. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hugues AD, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
9. Chen-Huan C, Nevo E, Fetics B, Pak PH, Yin FCP. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation. 1997;95:1827-1836.
10. London GM, Asmar RG, O'Rourke MF, Safar ME, and Reason Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-99.
11. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23:551-556.
12. Chen CH, Ting CT, Lin SJ, Hsu FCP, Siu CO, Chou P, Wang SP, Chang MS. Different effects of fosinopril and atenolol on wave reflections in hypertensive. Hypertension. 1995;25:1034-1041.
13. Ting CT, Chen C-H, Chang M-S, Yin FCP. Short- and long-term effects of antihypertensive drugs on arterial reflections compliance and impedance. Hypertension. 1995;26:524-530.
14. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a β-blocker or a calcium channel antagonist. J Hypertens. 1996;14:1247-1255.
15. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36:312-318.
16. Amar J, Ruidavets JB, Peyrieux JC, Mallion JM, Ferrieres J, Safar ME, Chamontin B. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension. 2005;46:151-155.
17. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension. 2002;39:197-202.
18. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, Messerli FH, Safar M. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933-1940.
19. Topouchian J, Asmar R, Sayegh F, Rudnichi A, Benetos A, Bacri AM, Safar ME. Changes in arterial structure and function under trandolaprilverapamil combination in hypertension. Stroke. 1999;30:1056-1064.
20. Yusuf S, Sleight P, Pogue J, Boch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
21. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S. Cardiovascular morbidity and mortality in the Losartan Intervention End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
22. De Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME, and Reason Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens. 2004;22:1623-1630.
23. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
24. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, De Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16:895-899.
25. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, Thomas F, Pannier B, Asmar R, Zureik M, Safar M, Guize L. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation. 2002;105:1202-1207.
26. Safar ME, Thomas F, Blacher J, Nzietchueng R, Bureau JM, Pannier B, Benetos A. Metabolic syndrome and age-related progression of aortic stiffness. J Am Coll Cardiol. 2006;47:72-75.
27. Levy BI, Ambrosio G, Pries AR, Struijker-boudier HAJ. Microcirculation in hypertension. A new target for treatment? Circulation. 2001;104:735-740.
28. Levy BI, Duriez M, Samuel JL. Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. Am J Hypertens. 2001;14:7-13.
29. Mitchell GF. Increased aortic stiffness: an unfavorable cardiorenal connection. Hypertension. 2004;43:151-153.
30. Essig M, Terzi F, Burtin M, Friedlander G. Mechanical strains induced by tubular flow affect the phenotype of proximal tubular cells. Am J Physiol. 2001;281:F751-F762.
31. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595-601.
32. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. Circ Res. 2002;90:1316-1324.
33. Verhave JC, Fesler P, Du Cailar G, Ribstein J, Safar ME, Mimram A. Elevated pulse pressure is associated with low renal function in elderly patients with isolated systolic hypertension. Hypertension. 2005;45:586-591.
34. Aoun S, Blacher J, Safar ME, Mourad JJ. Diabetes mellitus and renal failure: effects on large artery stiffness. J Hum Hypertens. 2001;15:693-700.
35. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.